(Q42689180)

4 November 2017

1 reference

title

Irinotecan: a new antineoplastic agent for the management of colorectal cancer (English)

1 reference

4 November 2017

1 reference

1 reference

R J Cersosimo

1

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

Annals of Pharmacotherapy

4 November 2017

published in

1 reference

4 November 2017

volume

32

1 reference

4 November 2017

issue

12

1 reference

4 November 2017

page(s)

1324-1333

1 reference

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

4 November 2017

cites work

1 reference

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

21 January 2018

1 reference

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

21 January 2018

1 reference

21 January 2018

Cancer statistics, 1998.

1 reference

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

21 January 2018

1 reference

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

21 January 2018

1 reference

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

21 January 2018

1 reference

Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer

21 January 2018

1 reference

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

21 January 2018

1 reference

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

21 January 2018

1 reference

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

21 January 2018

1 reference

Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.

21 January 2018

1 reference

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

21 January 2018

1 reference

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17462

1 reference

4 November 2017

1 reference